Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.The New England Journal of Medicine|April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Alessandra Mangia, David Wyles, et al.The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.Pageof 14